Genome Editing Market Size, Share, Growth & Forecast | 2031

Segments - Genome Editing Market by Technology (TALEN, ZFN, CRISPR, and Others), Application (Genetic Engineering, Drug Discovery, Gene-modified Cell Therapy, Diagnostics, Cell Line Engineering, and Others), End-user (Biotechnology & Pharma Companies, Contract Research Organization, Academics & Government Institutes, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

The global genome editing market size was USD 4,811.06 Mn in 2022 and is likely to reach USD 36,060.96 Mn by 2031, expanding at a CAGR of 22.31% during 2023–2031. Increasing number of genomics projects and rising production of genetically modified crops are anticipated to boost the market during the forecast period.

Genome editing is known as gene editing that involves group of technologies that allows researchers to change the DNA of an organism. This method allows alteration, addition, or removal of genes from specific locations of genome. It has application in cell line development in which cell lines are improved for considerable expression of therapeutic proteins with desired post translational modification. Furthermore, yeast cells were genetically modified to improve the production of biofuels. Crops and plants are genetically modified to enhance yield and harvest.

CRISPR-Cas9 is one of the advanced techniques used in genome editing. It is CRISPR-associated protein9 and short for regularly clustered regularly interspaced short palindrome repeats. Researcher believes that it is a rapid, cheap, and more efficient method compared to existing genome editing methods. Genome engineering has now become a potential transformative diagnostic tool, which is used by various government research centers for oncology studies.

The research report finds that the COVID-19 pandemic impacted the expansion of the genome editing market during the forecast period. Molecular biology tools including DETECTR, CARVER, PAC-MAN, ASO, CRISPR-Cas12/13-based SHERLOCK, ribozymes, aptamers, antisense peptide nucleic acids, and RNAi silencing therapies turn out to be more efficient than conventional treatment methods during the pandemic. Moreover, genome-wide association studies are new technique for discovering genes that are involved in human disease.

Genome Editing Market Dynamics

Major Drivers

Rising government funding is expected to drive the market in the coming years. Governments in several countries are investing in the field of genomics, which play a major role in the advancements of new technologies in genome editing. This investments and funding support the government institutes and academics to conduct various genome editing and engineering related projects. Genome editing technologies are helpful in managing rare diseases such as sickle-cell diseases and HIV.

In March 2020, the Ministry of Innovation, Science, and Industry (Science) invested USD 15 million for 11 genomic research projects in the agriculture, health, and environment sectors through Genome Canada. USD 29.7 million were invested by businesses, research partners, and regional government. These projects include the research on cervical and ovarian cancer.

Existing Restraints

High cost of genomic equipment and ethical concerns related to genetic research is projected to hamper the market expansion in the coming years. Genomic equipment has advanced functionalities and features, and thus the price of the equipment range between USD 10 to 20 million. High investments in multiple genomics instruments are not feasible for small and medium sized enterprises.

Emerging Opportunities

Increasing use of genome editing in personalized medicine is anticipated to create lucrative opportunities for market players. Medical practitioners identify medicine and treatment needs of patients with the help of personalized medicine. Personalized medicine is cost-effective and offers improved patient compliance, early detection of disease, and optimize various therapies.

Scope of the Genome Editing Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Genome Editing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Technology (TALEN, ZFN, CRISPR, and Others), Application (Genetic Engineering, Drug Discovery, Gene-modified Cell Therapy, Diagnostics, Cell Line Engineering, and Others), and End-user (Biotechnology & Pharma Companies, Contract Research Organization, Academics & Government Institutes, and Others)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
Key Players Covered in the Report	Agilent Technologies; GenScript; Horizon Discovery Limited; Lonza; Merck and Thermo Fisher Scientific; CRISPR Therapeutics; Danaher; Integrated DNA Technologies, Inc.; Eurofins Scientific; and Editas Medicine

Genome Editing Market Segment Insights

On the basis of technology, the genome editing market is segmented into TALEN, ZFN, CRISPR, and others. The CRISPR segment is projected to expand at a considerable CAGR during the forecast period, as it is used to generate chimeric antigen receptor T cells that are used to treat cancer. These T cells are extracted from patients and then treated to express chimeric antigen receptors before reinjecting into the body. Moreover, CRISPR/Cas9 treats thalassemia and sickle cell disease. The demand for CRISPR/Cas9 is increasing due to the enhanced efficiency of CRISPR/Cas9 in the identification and investigation of genetic disorders and drug discovery. The TALEN segment is anticipated to account for a major market share during the forecast period. TALEN is used to modify plant genomes to create cost-effective and nutritious food products.

Based on application, the market is divided into genetic engineering, drug discovery, gene-modified cell therapy, diagnostics, cell line engineering, and others. The gene-modified cell therapy segment is expected to hold a significant share of the market in the coming years, due to the increasing incidence of genetic disorders in several countries. Mutations and changes in the DNA sequence of an individual cause genetic diseases. Human genome editing methods are used on germline and somatic cells. Advanced genome editing techniques based on proteins include meganucleases, transcription activator-like effector nucleases (TALENs), and zinc-finger nucleases (ZFNs). The drug discovery segment accounts for a significant market share, owing to the rising technological advancements and high-grade equipment.

The cell line engineering segment is projected to register a considerable CAGR in the coming years, as it is used extensively in vaccine development, protein synthesis, drug development, and artificial tissue generation. Genetic mutations that cause diseases are corrected with the help of pluripotent stem cells (iPSCs) obtained through cell line engineering.

On the basis of end-user, the market is segregated into biotechnology & pharma companies, contract research organization, academics & government institutes, and others. The biotechnology & pharma companies segment is anticipated to expand at a substantial CAGR during the forecast period, due to the rising prevalence of infectious diseases and cancer. The biotech and pharma companies focused on producing genetically modified seeds and animals to maximize agricultural productivity. The academics & government institutes segment is expected to hold a significant share of the market in the coming years, owing to the increasing funding for genetic research.

In terms of region, the global genome editing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the global market during the forecast period, owing to rising use of genetically modified crops and presence of research grants in the region. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to the rising government initiatives and surging research and development activities on gene therapy in the region.

Segments

The global genome editing market has been segmented on the basis of

Technology

TALEN
ZFN
CRISPR
Others

Application

Genetic Engineering
Drug Discovery
Gene-modified Cell Therapy
Diagnostics
Cell Line Engineering
Others

End-user

Biotechnology & Pharma Companies
Contract Research Organization
Academics & Government Institutes
Others

Region

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Agilent Technologies
GenScript
Horizon Discovery Limited
Lonza
Merck and Thermo Fisher Scientific
CRISPR Therapeutics
Danaher
Integrated DNA Technologies, Inc.
Eurofins Scientific
Editas Medicine

Competitive Landscape

Key players competing in the global genome editing market are Agilent Technologies; GenScript; Horizon Discovery Limited; Lonza; Merck and Thermo Fisher Scientific; CRISPR Therapeutics; Danaher; Integrated DNA Technologies, Inc.; Eurofins Scientific; and Editas Medicine.

Numerous players are based in emerging countries, due to the maximum technological advancements and ease of connectivity in modern times. Rapid advancements in developing countries offers new opportunities to market players.

In February 2022, Integrated DNA Technologies unveiled Alt-R HDR donor blocks to serve the needs of researchers to push homology-directed repair genome editing research operations. Alt-R HDR Donor Blocks help scientists identify repairing disease-causing gene mutations and altering genomes to study the underlying genetic causes and treat genetic disorders.
In October 2021, Merck KGaA a leading science and technology company, licensed its CRISPR-Cas9 technology, which is patented, to Cellecta for the improvement in next-generation treatments. This allowed Scientists and researchers to advance treatments for cancers, genetic blood disorders, and ophthalmological diseases.
In May 2019, Thermo Fisher Scientific acquired Brammer Bio to upsurge its global presence in the market with the addition of the expertise of Brammer Bio in the manufacturing of vectors for genes and cell therapies.

Genome Editing Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Genome Editing Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Genome Editing Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Genome Editing Market - Supply Chain
  4.5. Global Genome Editing Market Forecast
     4.5.1. Genome Editing Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Genome Editing Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Genome Editing Market Absolute $ Opportunity
5. Global Genome Editing Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Genome Editing Market Size and Volume Forecast by Applications
     5.3.1. Genetic Engineering
     5.3.2. Drug Discovery
     5.3.3. Gene-modified Cell Therapy
     5.3.4. Diagnostics
     5.3.5. Cell Line Engineering
     5.3.6. Others
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Genome Editing Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Genome Editing Market Size and Volume Forecast by End Users
     6.3.1. Biotechnology & Pharma Companies
     6.3.2. Contract Research Organization
     6.3.3. Academics & Government Institutes
     6.3.4. Others
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Genome Editing Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Genome Editing Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Genome Editing Demand Share Forecast, 2019-2026
8. North America Genome Editing Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Genome Editing Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Genome Editing Market Size and Volume Forecast by Applications
     8.4.1. Genetic Engineering
     8.4.2. Drug Discovery
     8.4.3. Gene-modified Cell Therapy
     8.4.4. Diagnostics
     8.4.5. Cell Line Engineering
     8.4.6. Others
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. North America Genome Editing Market Size and Volume Forecast by End Users
     8.7.1. Biotechnology & Pharma Companies
     8.7.2. Contract Research Organization
     8.7.3. Academics & Government Institutes
     8.7.4. Others
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Genome Editing Demand Share Forecast, 2019-2026
9. Latin America Genome Editing Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Genome Editing Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Genome Editing Market Size and Volume Forecast by Applications
     9.4.1. Genetic Engineering
     9.4.2. Drug Discovery
     9.4.3. Gene-modified Cell Therapy
     9.4.4. Diagnostics
     9.4.5. Cell Line Engineering
     9.4.6. Others
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Latin America Genome Editing Market Size and Volume Forecast by End Users
     9.7.1. Biotechnology & Pharma Companies
     9.7.2. Contract Research Organization
     9.7.3. Academics & Government Institutes
     9.7.4. Others
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Genome Editing Demand Share Forecast, 2019-2026
10. Europe Genome Editing Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Genome Editing Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Genome Editing Market Size and Volume Forecast by Applications
     10.4.1. Genetic Engineering
     10.4.2. Drug Discovery
     10.4.3. Gene-modified Cell Therapy
     10.4.4. Diagnostics
     10.4.5. Cell Line Engineering
     10.4.6. Others
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Europe Genome Editing Market Size and Volume Forecast by End Users
     10.7.1. Biotechnology & Pharma Companies
     10.7.2. Contract Research Organization
     10.7.3. Academics & Government Institutes
     10.7.4. Others
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Genome Editing Demand Share Forecast, 2019-2026
11. Asia Pacific Genome Editing Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Genome Editing Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Genome Editing Market Size and Volume Forecast by Applications
     11.4.1. Genetic Engineering
     11.4.2. Drug Discovery
     11.4.3. Gene-modified Cell Therapy
     11.4.4. Diagnostics
     11.4.5. Cell Line Engineering
     11.4.6. Others
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Asia Pacific Genome Editing Market Size and Volume Forecast by End Users
     11.7.1. Biotechnology & Pharma Companies
     11.7.2. Contract Research Organization
     11.7.3. Academics & Government Institutes
     11.7.4. Others
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Genome Editing Demand Share Forecast, 2019-2026
12. Middle East & Africa Genome Editing Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Genome Editing Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Genome Editing Market Size and Volume Forecast by Applications
     12.4.1. Genetic Engineering
     12.4.2. Drug Discovery
     12.4.3. Gene-modified Cell Therapy
     12.4.4. Diagnostics
     12.4.5. Cell Line Engineering
     12.4.6. Others
  12.5. Basis Point Share (BPS) Analysis by Applications
  12.6. Y-o-Y Growth Projections by Applications
  12.7. Middle East & Africa Genome Editing Market Size and Volume Forecast by End Users
     12.7.1. Biotechnology & Pharma Companies
     12.7.2. Contract Research Organization
     12.7.3. Academics & Government Institutes
     12.7.4. Others
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Genome Editing Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Genome Editing Market: Market Share Analysis
  13.2. Genome Editing Distributors and Customers
  13.3. Genome Editing Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Agilent Technologies
     13.4.2. GenScript
     13.4.3. Horizon Discovery Limited
     13.4.4. Lonza
     13.4.5. Merck and Thermo Fisher Scientific
     13.4.6. CRISPR Therapeutics
     13.4.7. Danaher
     13.4.8. Eurofins Scientific
     13.4.9. Editas Medicine